# Coinbase Global, Inc.: financial statements, quarterly

COIN · Nasdaq · CIK 1679788 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coin.md) · [Financials](/companies/coin/financials.md) · [Filings](/companies/coin/filings.md) · [Insiders](/companies/coin/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coin/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [674](/filings/0001679788-24-000187.md) | [954 d](/filings/0001679788-26-000015.md) | [1,638](/filings/0001679788-25-000089.md) | [1,450](/filings/0001679788-25-000154.md) | [1,205](/filings/0001679788-25-000208.md) | [2,272 d](/filings/0001679788-26-000015.md) | [2,034](/filings/0001679788-26-000054.md) | [1,497](/filings/0001679788-26-000088.md) | [1,869](/filings/0001679788-25-000208.md) | [1,781 d](/filings/0001679788-26-000015.md) | [1,413](/filings/0001679788-26-000054.md) | [1,220](/filings/0001679788-26-000088.md) |
| Research and development | $m | [323](/filings/0001679788-24-000187.md) | [323 d](/filings/0001679788-26-000015.md) | [358](/filings/0001679788-25-000089.md) | [364](/filings/0001679788-25-000154.md) | [377](/filings/0001679788-25-000208.md) | [369 d](/filings/0001679788-26-000015.md) | [355](/filings/0001679788-26-000054.md) | [387](/filings/0001679788-26-000088.md) | [431](/filings/0001679788-25-000208.md) | [497 d](/filings/0001679788-26-000015.md) | [526](/filings/0001679788-26-000054.md) | [473](/filings/0001679788-26-000088.md) |
| Operating income | $m | [(79.8)](/filings/0001679788-24-000187.md) | [116 d](/filings/0001679788-26-000015.md) | [760](/filings/0001679788-25-000089.md) | [343](/filings/0001679788-25-000154.md) | [170](/filings/0001679788-25-000208.md) | [1,034 d](/filings/0001679788-26-000015.md) | [706](/filings/0001679788-26-000054.md) | [(24.7)](/filings/0001679788-26-000088.md) | [481](/filings/0001679788-25-000208.md) | [274 d](/filings/0001679788-26-000015.md) | [(21.4)](/filings/0001679788-26-000054.md) | [(113)](/filings/0001679788-26-000088.md) |
| Interest expense | $m | [20.8](/filings/0001679788-23-000113.md) | [18.7 d](/filings/0001679788-24-000022.md) | [19.1](/filings/0001679788-24-000089.md) | [20.5](/filings/0001679788-25-000154.md) | [20.5](/filings/0001679788-25-000208.md) | [20.5 d](/filings/0001679788-26-000015.md) | [20.5](/filings/0001679788-26-000054.md) | [20.5](/filings/0001679788-26-000088.md) | [21.8](/filings/0001679788-25-000208.md) | [22.6 d](/filings/0001679788-26-000015.md) | [22.6](/filings/0001679788-26-000054.md) | [22.5](/filings/0001679788-26-000088.md) |
| Income tax | $m | [36.9](/filings/0001679788-24-000187.md) | [(141) d](/filings/0001679788-26-000015.md) | [261](/filings/0001679788-25-000089.md) | [(96.4)](/filings/0001679788-25-000154.md) | [(6.9)](/filings/0001679788-25-000208.md) | [206 d](/filings/0001679788-26-000015.md) | [16.8](/filings/0001679788-26-000054.md) | [395](/filings/0001679788-26-000088.md) | [69.6](/filings/0001679788-25-000208.md) | [(220) d](/filings/0001679788-26-000015.md) | [(70.6)](/filings/0001679788-26-000054.md) | [(35.9)](/filings/0001679788-26-000088.md) |
| Net income | $m | [(2.3)](/filings/0001679788-24-000187.md) | [273 d](/filings/0001679788-26-000015.md) | [1,176](/filings/0001679788-25-000089.md) | [36.2](/filings/0001679788-25-000154.md) | [75.5](/filings/0001679788-25-000208.md) | [1,291 d](/filings/0001679788-26-000015.md) | [65.6](/filings/0001679788-26-000054.md) | [1,429](/filings/0001679788-26-000088.md) | [433](/filings/0001679788-25-000208.md) | [(667) d](/filings/0001679788-26-000015.md) | [(394)](/filings/0001679788-26-000054.md) | [(359)](/filings/0001679788-26-000088.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001679788-24-000187.md) | not reported | [4.40](/filings/0001679788-25-000089.md) | [0.14](/filings/0001679788-25-000154.md) | [0.28](/filings/0001679788-25-000208.md) | not reported | [0.24](/filings/0001679788-26-000054.md) | [5.14](/filings/0001679788-26-000088.md) | [1.50](/filings/0001679788-25-000208.md) | not reported | [(1.49)](/filings/0001679788-26-000054.md) | [(1.36)](/filings/0001679788-26-000088.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001679788-24-000187.md) | not reported | [4.84](/filings/0001679788-25-000089.md) | [0.15](/filings/0001679788-25-000154.md) | [0.30](/filings/0001679788-25-000208.md) | not reported | [0.26](/filings/0001679788-26-000054.md) | [5.60](/filings/0001679788-26-000088.md) | [1.65](/filings/0001679788-25-000208.md) | not reported | [(1.49)](/filings/0001679788-26-000054.md) | [(1.36)](/filings/0001679788-26-000088.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [5.1](/filings/0001679788-24-000187.md) | [5.5](/filings/0001679788-26-000015.md) | [6.7](/filings/0001679788-25-000089.md) | [7.2](/filings/0001679788-25-000154.md) | [7.7](/filings/0001679788-25-000208.md) | [9.3](/filings/0001679788-26-000015.md) | [10.0](/filings/0001679788-26-000054.md) | [9.4](/filings/0001679788-26-000088.md) | [8.7](/filings/0001679788-25-000208.md) | [11.3](/filings/0001679788-26-000088.md) | [10.2](/filings/0001679788-26-000054.md) | [8.6](/filings/0001679788-26-000088.md) |
| Current assets | $bn | [124](/filings/0001679788-23-000113.md) | [11.4](/filings/0001679788-25-000022.md) | [344](/filings/0001679788-24-000089.md) | [283](/filings/0001679788-24-000149.md) | [286](/filings/0001679788-24-000187.md) | [18.1](/filings/0001679788-26-000015.md) | [17.5](/filings/0001679788-25-000089.md) | [17.5](/filings/0001679788-25-000154.md) | [22.1](/filings/0001679788-25-000208.md) | [20.4](/filings/0001679788-26-000088.md) | [19.7](/filings/0001679788-26-000054.md) | [17.5](/filings/0001679788-26-000088.md) |
| Total assets | $bn | [127](/filings/0001679788-23-000113.md) | [14.8](/filings/0001679788-25-000022.md) | [348](/filings/0001679788-24-000089.md) | [287](/filings/0001679788-24-000149.md) | [291](/filings/0001679788-24-000187.md) | [22.5](/filings/0001679788-26-000015.md) | [21.7](/filings/0001679788-25-000089.md) | [23.5](/filings/0001679788-25-000154.md) | [31.4](/filings/0001679788-25-000208.md) | [29.7](/filings/0001679788-26-000088.md) | [28.8](/filings/0001679788-26-000054.md) | [26.5](/filings/0001679788-26-000088.md) |
| Current liabilities | $bn | [118](/filings/0001679788-23-000113.md) | [5.5](/filings/0001679788-25-000022.md) | [336](/filings/0001679788-24-000089.md) | [274](/filings/0001679788-24-000149.md) | [278](/filings/0001679788-24-000187.md) | [7.9](/filings/0001679788-26-000015.md) | [6.9](/filings/0001679788-25-000089.md) | [8.2](/filings/0001679788-25-000154.md) | [9.2](/filings/0001679788-25-000208.md) | [8.7](/filings/0001679788-26-000088.md) | [9.2](/filings/0001679788-26-000054.md) | [7.2](/filings/0001679788-26-000088.md) |
| Total liabilities | $bn | [121](/filings/0001679788-23-000113.md) | [8.5](/filings/0001679788-25-000022.md) | [340](/filings/0001679788-24-000089.md) | [279](/filings/0001679788-24-000149.md) | [282](/filings/0001679788-24-000187.md) | [12.3](/filings/0001679788-26-000015.md) | [11.3](/filings/0001679788-25-000089.md) | [11.4](/filings/0001679788-25-000154.md) | [15.3](/filings/0001679788-25-000208.md) | [14.9](/filings/0001679788-26-000088.md) | [15.4](/filings/0001679788-26-000054.md) | [13.4](/filings/0001679788-26-000088.md) |
| Long-term debt | $bn | [3.1](/filings/0001679788-23-000113.md) | [3.0](/filings/0001679788-25-000022.md) | [4.2](/filings/0001679788-24-000089.md) | [4.2](/filings/0001679788-24-000149.md) | [4.2](/filings/0001679788-24-000187.md) | [4.2](/filings/0001679788-26-000015.md) | [4.2](/filings/0001679788-25-000089.md) | [3.0](/filings/0001679788-25-000154.md) | [5.9](/filings/0001679788-25-000208.md) | [5.9](/filings/0001679788-26-000088.md) | [5.9](/filings/0001679788-26-000054.md) | [5.9](/filings/0001679788-26-000088.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001679788-26-000015.md) | not reported | [1.3](/filings/0001679788-25-000154.md) | [1.3](/filings/0001679788-25-000208.md) | [1.3](/filings/0001679788-26-000088.md) | [1.3](/filings/0001679788-26-000054.md) | [0.0](/filings/0001679788-26-000088.md) |
| Short-term borrowings | $bn | [0.0](/filings/0001679788-23-000113.md) | [0.0](/filings/0001679788-24-000022.md) | not reported | not reported | not reported | [0.4](/filings/0001679788-26-000015.md) | not reported | not reported | not reported | [0.5](/filings/0001679788-26-000088.md) | [0.6](/filings/0001679788-26-000054.md) | [0.5](/filings/0001679788-26-000088.md) |
| Shareholders' equity | $bn | [5.9](/filings/0001679788-24-000187.md) | [6.3](/filings/0001679788-26-000015.md) | [8.1](/filings/0001679788-25-000154.md) | [8.4](/filings/0001679788-25-000208.md) | [8.7](/filings/0001679788-25-000208.md) | [10.3](/filings/0001679788-26-000088.md) | [10.5](/filings/0001679788-26-000088.md) | [12.1](/filings/0001679788-26-000088.md) | [16.0](/filings/0001679788-25-000208.md) | [14.8](/filings/0001679788-26-000088.md) | [13.5](/filings/0001679788-26-000088.md) | [13.1](/filings/0001679788-26-000088.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [314 d](/filings/0001679788-24-000187.md) | [(255) d](/filings/0001679788-26-000015.md) | [411](/filings/0001679788-25-000089.md) | [484 d](/filings/0001679788-25-000154.md) | [697 d](/filings/0001679788-25-000208.md) | [1,512 d](/filings/0001679788-26-000015.md) | [853](/filings/0001679788-26-000054.md) | [240 d](/filings/0001679788-26-000088.md) | [(1,732) d](/filings/0001679788-25-000208.md) | [3,065 d](/filings/0001679788-26-000015.md) | [183](/filings/0001679788-26-000054.md) | [197 d](/filings/0001679788-26-000088.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001679788-23-000113.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001679788-26-000054.md) | [0.0 d](/filings/0001679788-26-000088.md) | not reported | not reported | [1,062](/filings/0001679788-26-000054.md) | [181 d](/filings/0001679788-26-000088.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [224](/filings/0001679788-23-000113.md) | [231](/filings/0001679788-24-000089.md) | [235](/filings/0001679788-24-000149.md) | [237](/filings/0001679788-24-000187.md) | [268](/filings/0001679788-25-000089.md) | [267](/filings/0001679788-25-000154.md) | [267](/filings/0001679788-25-000208.md) | [271](/filings/0001679788-26-000054.md) | [279](/filings/0001679788-26-000088.md) | [292](/filings/0001679788-25-000208.md) | [265](/filings/0001679788-26-000054.md) | [263](/filings/0001679788-26-000088.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.